Format

Send to

Choose Destination
Dermatol Surg. 2018 Sep;44(9):1183-1190. doi: 10.1097/DSS.0000000000001584.

Injectable Platelet-, Leukocyte-, and Fibrin-Rich Plasma (iL-PRF) in the Management of Androgenetic Alopecia.

Author information

1
Plastic Surgery and Regenerative Surgery Unit, IDI-IRCCS, FLMM, Rome, Italy.
2
Dermatology Unit, "Cristo Re" General Hospital, Rome, Italy.
3
Dermatological Day Surgery Unit, IDI-IRCCS, FLMM, Rome, Italy.
4
Clinical Epidemiology Unit, IDI-IRCCS, FLMM, Rome, Italy.

Abstract

BACKGROUND:

The role of enriched autologous plasmas in androgenetic alopecia (AGA) management is emerging in recent literature.

OBJECTIVE:

In this prospective study, the authors aimed to confirm that the induction of a minor local trauma immediately followed by injections of an enriched plasma made of a strongly concentrated platelet fraction, a robust white cell presence, concentrated fibrinogen, and other plasma proteins (injectable leukocyte platelet-rich fibrin [iL-PRF]) could be able to produce positive clinical results in patients with AGA.

MATERIALS AND METHODS:

A 2-injection regimen was instituted, with a 3-month interval between the 2 interventions. A treatment group (TG) and a control group (CG) were instituted. Macrophotographs were taken at baseline and after 6 months, and rated by 5-people expert panel (blinded to this assignment) using the 15-point scale proposed by Jaeschke to evaluate the clinical change.

RESULTS:

Overall, TG showed better scores compared with the CG in all 5 classes of global physician assessment at baseline, all age groups, and in both sexes, and such differences always reached statistical significance. A greater severity at baseline showed a larger improvement after treatment in the TG.

CONCLUSION:

This study provides preliminary evidence that the biological composition of the iL-PRF is of crucial importance in ensuring a good degree of clinical efficacy in patients with AGA.

PMID:
30045107
DOI:
10.1097/DSS.0000000000001584
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center